Follow us:
  • EnglishEnglish
  • FrançaisFrançais
  • EspañolEspañol
GUT MICROBIOTA FOR HEALTH GUT MICROBIOTA FOR HEALTH GUT MICROBIOTA FOR HEALTH

Sign up for our newsletters and do not miss any updates

  • Home
  • News Watch
  • Research & practice
  • About Gut Microbiota
  • Events
  • Resources
  • Media center
    GUT MICROBIOTA FOR HEALTH GUT MICROBIOTA FOR HEALTH GUT MICROBIOTA FOR HEALTH
    • Home
      • Gut Microbiota
      • Metabolic Conditions
      • Digestive Health
      • Gut Brain Axis
      • Immune Health
      • Nutrition
      • Probiotics
      • Pregnancy & early life
    • News Watch
      • Gut microbiota
      • Metabolic conditions
      • Digestive health
      • Gut brain axis
      • Immune health
      • Nutrition
      • Probiotics
      • Pregnancy & early life
    • Research & practice
      • Gut microbiota
      • Metabolic conditions
      • Digestive health
      • Gut brain axis
      • Immune health
      • Nutrition
      • Probiotics
      • Pregnancy & early life
    • About Gut Microbiota
      • Gut microbiota info
      • Diet & Gut Microbiota
    • Events
      • Calendar
      • Reports
      • Gut Microbiota for Health World Summit 2020
    • Resources
      • Video
      • Infographics
      • E-learning
      • Glossary
      • Links
      • Publications
    • Media center
      • Gut Microbiota
      • Metabolic Conditions
      • Digestive Health
      • Gut Brain Axis
      • Immune Health
      • Nutrition
      • Probiotics
      • Pregnancy & early life
    • EnglishEnglish
    • FrançaisFrançais
    • EspañolEspañol

    Sign up for our newsletters and do not miss any updates

    Search Results for: ulcerative colitis

    Baseline gut microbiome is associated with disease severity, progression and treatment efficacy in pediatric ulcerative colitis patients

    • 26 Nov 2018
    • BY Andreu Prados
    • In Digestive Health, IBD, Research & Practice, Ulcerative Colitis
    • No Comment
    • 0

    Recent research has involved genetics, altered mucosal immune responses, environmental factors and the gut microbiome as major players in the development of inflammatory bowel disease (IBD). Given that some patients do not respond to conventional treatments, scientists are currently exploring new gut microbiome-targeted therapeutic approaches to improve disease course. A new study, led by Dr. Ramnik Joseph Xavier from the…

    Andreu Prados
    Andreu Prados holds a Bachelor of Science Degree in Pharmacy & Human Nutrition and Dietetics. Science writer specialised in gut microbiota and probiotics, working also as lecturer and consultant in nutrition and healthcare. Follow Andreu on Twitter @andreuprados
    Share:

    Baseline gut microbiome is associated with disease severity, progression and treatment efficacy in pediatric ulcerative colitis patients

    • 26 Nov 2018
    • BY Andreu Prados
    • In Digestive Health, IBD, Research & Practice, Ulcerative Colitis
    • No Comment
    • 0

    Recent research has involved genetics, altered mucosal immune responses, environmental factors and the gut microbiome as major players in the development of inflammatory bowel disease (IBD). Given that some patients do not respond to conventional treatments, scientists are currently exploring new gut microbiome-targeted therapeutic approaches to improve disease course. A new study, led by Dr. Ramnik Joseph Xavier from the…

    Andreu Prados
    Andreu Prados holds a Bachelor of Science Degree in Pharmacy & Human Nutrition and Dietetics. Science writer specialised in gut microbiota and probiotics, working also as lecturer and consultant in nutrition and healthcare. Follow Andreu on Twitter @andreuprados
    Share: /* */

    Faecal microbiota transplantation may improve active ulcerative colitis

    • 20 Apr 2017
    • BY Paul Enck
    • In Fecal Microbiota Transplant, Gut Microbiota, IBD, Research & Practice, Ulcerative Colitis
    • No Comment
    • 0

    Faecal microbiota transplantation (FMT) is a therapy targeting the gut microbiome with the strongest evidence for efficacy in the treatment of recurrent Clostridium difficile infection. Although gut microbiota dysbiosis is involved in the pathogenesis of ulcerative colitis, the role of FMT as a therapy for it is still controversial as the two big randomised controlled trials done previously (here; here)…

    Paul Enck
    Prof. Dr. Paul Enck, Director of Research, Dept. of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Germany. His main interests are gut functions in health and disease, including functional and inflammatory bowel disorders, the role of the gut microbiota, regulation of eating and food intake and its disorders, of nausea, vomiting and motion sickness, and the psychophysiology and neurobiology of the placebo response, with specific emphasis on age and gender contributions. He has published more than 170 original data paper in scientific, peer-reviewed journals, and more than 250 book chapters and review articles. He is board member/treasurer of the European Society of Neurogastroenterology and Motility and of the German Society of Neurogastroenterology and Motility, and has served as reviewer for many international journals and grant agencies.
    Share:

    Faecal microbiota transplantation may improve active ulcerative colitis

    • 20 Apr 2017
    • BY Paul Enck
    • In Fecal Microbiota Transplant, Gut Microbiota, IBD, Research & Practice, Ulcerative Colitis
    • No Comment
    • 0

    Faecal microbiota transplantation (FMT) is a therapy targeting the gut microbiome with the strongest evidence for efficacy in the treatment of recurrent Clostridium difficile infection. Although gut microbiota dysbiosis is involved in the pathogenesis of ulcerative colitis, the role of FMT as a therapy for it is still controversial as the two big randomised controlled trials done previously (here; here)…

    Paul Enck
    Prof. Dr. Paul Enck, Director of Research, Dept. of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Germany. His main interests are gut functions in health and disease, including functional and inflammatory bowel disorders, the role of the gut microbiota, regulation of eating and food intake and its disorders, of nausea, vomiting and motion sickness, and the psychophysiology and neurobiology of the placebo response, with specific emphasis on age and gender contributions. He has published more than 170 original data paper in scientific, peer-reviewed journals, and more than 250 book chapters and review articles. He is board member/treasurer of the European Society of Neurogastroenterology and Motility and of the German Society of Neurogastroenterology and Motility, and has served as reviewer for many international journals and grant agencies.
    Share: /* */

    New strategy may increase the success of FMT for ulcerative colitis

    • 8 Nov 2015
    • BY Kristina Campbell
    • In Fecal Microbiota Transplant, Gut Microbiota, HCP, Research & Practice, Ulcerative Colitis
    • No Comment
    • 0

    Fecal microbiota transplantation (FMT) for patients with ulcerative colitis (UC) has shown mixed clinical results (see recent trials here and here). In a new pilot study, published as open access, Faming Zhang and colleagues tested the safety and efficacy of a "step-up" FMT strategy in 15 steroid-dependent UC patients. The step-up strategy was as follows: After all medications were discontinued,…

    Kristina Campbell
    Science writer Kristina Campbell (M.Sc.), from British Columbia (Canada), specializes in communicating about the gut microbiota, digestive health, and nutrition. Author of the best selling Well-Fed Microbiome Cookbook, her freelance work has appeared in publications around the world. Kristina joined the Gut Microbiota for Health publishing team in 2014.  Find her on: Google • Twitter
    Share:

    New strategy may increase the success of FMT for ulcerative colitis

    • 8 Nov 2015
    • BY Kristina Campbell
    • In Fecal Microbiota Transplant, Gut Microbiota, HCP, Research & Practice, Ulcerative Colitis
    • No Comment
    • 0

    Fecal microbiota transplantation (FMT) for patients with ulcerative colitis (UC) has shown mixed clinical results (see recent trials here and here). In a new pilot study, published as open access, Faming Zhang and colleagues tested the safety and efficacy of a "step-up" FMT strategy in 15 steroid-dependent UC patients. The step-up strategy was as follows: After all medications were discontinued,…

    Kristina Campbell
    Science writer Kristina Campbell (M.Sc.), from British Columbia (Canada), specializes in communicating about the gut microbiota, digestive health, and nutrition. Author of the best selling Well-Fed Microbiome Cookbook, her freelance work has appeared in publications around the world. Kristina joined the Gut Microbiota for Health publishing team in 2014.  Find her on: Google • Twitter
    Share: /* */

    FMT for ulcerative colitis holds promise despite discontinued Canadian trial, says Moayyedi

    • 20 Jul 2015
    • BY Kristina Campbell
    • In Fecal Microbiota Transplant, Gut Microbiota, Research & Practice, Ulcerative Colitis
    • 4 Comments
    • 0

    Dr. Paul Moayyedi, a gastroenterologist and researcher at McMaster University in Hamilton, Canada, was the first author of a study published earlier this year that investigated fecal microbiota transplantation (FMT) as a way to induce remission in patients with ulcerative colitis (UC). (See the study summary here.) Although patient recruitment was discontinued at the study's halfway point for reasons of…

    Kristina Campbell
    Science writer Kristina Campbell (M.Sc.), from British Columbia (Canada), specializes in communicating about the gut microbiota, digestive health, and nutrition. Author of the best selling Well-Fed Microbiome Cookbook, her freelance work has appeared in publications around the world. Kristina joined the Gut Microbiota for Health publishing team in 2014.  Find her on: Google • Twitter
    Share:

    FMT for ulcerative colitis holds promise despite discontinued Canadian trial, says Moayyedi

    • 20 Jul 2015
    • BY Kristina Campbell
    • In Fecal Microbiota Transplant, Gut Microbiota, Research & Practice, Ulcerative Colitis
    • 4 Comments
    • 0

    Dr. Paul Moayyedi, a gastroenterologist and researcher at McMaster University in Hamilton, Canada, was the first author of a study published earlier this year that investigated fecal microbiota transplantation (FMT) as a way to induce remission in patients with ulcerative colitis (UC). (See the study summary here.) Although patient recruitment was discontinued at the study's halfway point for reasons of…

    Kristina Campbell
    Science writer Kristina Campbell (M.Sc.), from British Columbia (Canada), specializes in communicating about the gut microbiota, digestive health, and nutrition. Author of the best selling Well-Fed Microbiome Cookbook, her freelance work has appeared in publications around the world. Kristina joined the Gut Microbiota for Health publishing team in 2014.  Find her on: Google • Twitter
    Share: /* */

    Further investigation of fecal microbiota transplantation to treat ulcerative colitis

    • 12 May 2015
    • BY Paul Enck
    • In Fecal Microbiota Transplant, Gut Microbiota, Research & Practice, Ulcerative Colitis
    • 2 Comments
    • 0

    Amsterdam researchers recently published an investigation of fecal microbiota transplantation (FMT) for the treatment of ulcerative colitis (UC). The TURN trial -- Transplantation of feces in Ulcerative colitis; Returning Nature's homeostasis -- was a double-blind randomized trial with 48 subjects who had mild to moderatively active UC. Participants received either a healthy donor's feces or their own feces (i.e. autologous…

    Paul Enck
    Prof. Dr. Paul Enck, Director of Research, Dept. of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Germany. His main interests are gut functions in health and disease, including functional and inflammatory bowel disorders, the role of the gut microbiota, regulation of eating and food intake and its disorders, of nausea, vomiting and motion sickness, and the psychophysiology and neurobiology of the placebo response, with specific emphasis on age and gender contributions. He has published more than 170 original data paper in scientific, peer-reviewed journals, and more than 250 book chapters and review articles. He is board member/treasurer of the European Society of Neurogastroenterology and Motility and of the German Society of Neurogastroenterology and Motility, and has served as reviewer for many international journals and grant agencies.
    Share:

    Further investigation of fecal microbiota transplantation to treat ulcerative colitis

    • 12 May 2015
    • BY Paul Enck
    • In Fecal Microbiota Transplant, Gut Microbiota, Research & Practice, Ulcerative Colitis
    • 2 Comments
    • 0

    Amsterdam researchers recently published an investigation of fecal microbiota transplantation (FMT) for the treatment of ulcerative colitis (UC). The TURN trial -- Transplantation of feces in Ulcerative colitis; Returning Nature's homeostasis -- was a double-blind randomized trial with 48 subjects who had mild to moderatively active UC. Participants received either a healthy donor's feces or their own feces (i.e. autologous…

    Paul Enck
    Prof. Dr. Paul Enck, Director of Research, Dept. of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Germany. His main interests are gut functions in health and disease, including functional and inflammatory bowel disorders, the role of the gut microbiota, regulation of eating and food intake and its disorders, of nausea, vomiting and motion sickness, and the psychophysiology and neurobiology of the placebo response, with specific emphasis on age and gender contributions. He has published more than 170 original data paper in scientific, peer-reviewed journals, and more than 250 book chapters and review articles. He is board member/treasurer of the European Society of Neurogastroenterology and Motility and of the German Society of Neurogastroenterology and Motility, and has served as reviewer for many international journals and grant agencies.
    Share: /* */

    New Study Investigating Fecal Microbiota Transplantation to Treat Active Ulcerative Colitis

    • 14 Apr 2015
    • BY Paul Enck
    • In Fecal Microbiota Transplant, Gut Microbiota, Research & Practice, Ulcerative Colitis
    • 1 Comment
    • 0

    Moayyedi et al. from Canada recently published a paper entitled Fecal Microbiota Transplantation Induces Remission in Patients with Active Ulcerative Colitis in a Randomized, Controlled Trial. Authors investigated the safety and efficacy of fecal microbiota transplantation (FMT) to treat active ulcerative colitis (UC) without infectious diarrhea; they say it is the largest placebo-controlled, randomized trial for FMT to treat any…

    Paul Enck
    Prof. Dr. Paul Enck, Director of Research, Dept. of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Germany. His main interests are gut functions in health and disease, including functional and inflammatory bowel disorders, the role of the gut microbiota, regulation of eating and food intake and its disorders, of nausea, vomiting and motion sickness, and the psychophysiology and neurobiology of the placebo response, with specific emphasis on age and gender contributions. He has published more than 170 original data paper in scientific, peer-reviewed journals, and more than 250 book chapters and review articles. He is board member/treasurer of the European Society of Neurogastroenterology and Motility and of the German Society of Neurogastroenterology and Motility, and has served as reviewer for many international journals and grant agencies.
    Share:

    New Study Investigating Fecal Microbiota Transplantation to Treat Active Ulcerative Colitis

    • 14 Apr 2015
    • BY Paul Enck
    • In Fecal Microbiota Transplant, Gut Microbiota, Research & Practice, Ulcerative Colitis
    • 1 Comment
    • 0

    Moayyedi et al. from Canada recently published a paper entitled Fecal Microbiota Transplantation Induces Remission in Patients with Active Ulcerative Colitis in a Randomized, Controlled Trial. Authors investigated the safety and efficacy of fecal microbiota transplantation (FMT) to treat active ulcerative colitis (UC) without infectious diarrhea; they say it is the largest placebo-controlled, randomized trial for FMT to treat any…

    Paul Enck
    Prof. Dr. Paul Enck, Director of Research, Dept. of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Germany. His main interests are gut functions in health and disease, including functional and inflammatory bowel disorders, the role of the gut microbiota, regulation of eating and food intake and its disorders, of nausea, vomiting and motion sickness, and the psychophysiology and neurobiology of the placebo response, with specific emphasis on age and gender contributions. He has published more than 170 original data paper in scientific, peer-reviewed journals, and more than 250 book chapters and review articles. He is board member/treasurer of the European Society of Neurogastroenterology and Motility and of the German Society of Neurogastroenterology and Motility, and has served as reviewer for many international journals and grant agencies.
    Share: /* */

    Probiotics and Heat Shock Proteins in Ulcerative Colitis

    • 5 Jan 2015
    • BY Marcello Romeo
    • In IBD, Inflammation, Probiotics, Research & Practice
    • 1 Comment
    • 0

    The Inflammatory Bowel Diseases (IBDs), which include Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic relapsing and remitting inflammatory disorders of the gastrointestinal tract. The etiology of IBDs is not known yet but it is certainly multi-factorial and it includes genetic as well as environmental factors. Over the last years it has become clear, however, that IBD develops in genetically…

    Marcello Romeo
    Dr Marcello Romeo is currently at PHD School in Molecular and Experimental Medicine at Department of Experimental Biomedicine and Clinical Neuroscience at University of Palermo (Italy). His main research interest is the molecular assessment of the Human Intestinal Microbiota in health and disease and investigation of the molecular cross-talk between intestinal bacteria and Heat Shock Proteins in colon mucosa of Inflammatory Bowel Disease and Colon Cancer.
    Share:

    Probiotics and Heat Shock Proteins in Ulcerative Colitis

    • 5 Jan 2015
    • BY Marcello Romeo
    • In IBD, Inflammation, Probiotics, Research & Practice
    • 1 Comment
    • 0

    The Inflammatory Bowel Diseases (IBDs), which include Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic relapsing and remitting inflammatory disorders of the gastrointestinal tract. The etiology of IBDs is not known yet but it is certainly multi-factorial and it includes genetic as well as environmental factors. Over the last years it has become clear, however, that IBD develops in genetically…

    Marcello Romeo
    Dr Marcello Romeo is currently at PHD School in Molecular and Experimental Medicine at Department of Experimental Biomedicine and Clinical Neuroscience at University of Palermo (Italy). His main research interest is the molecular assessment of the Human Intestinal Microbiota in health and disease and investigation of the molecular cross-talk between intestinal bacteria and Heat Shock Proteins in colon mucosa of Inflammatory Bowel Disease and Colon Cancer.
    Share: /* */

    A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.

    • 10 Jan 2014
    • BY Philippe Marteau
    • In Dysbiosis, Gut Microbiota, HCP, Research & Practice, SCFA, Ulcerative Colitis
    • No Comment
    • 0

    Machiels et al. recently described that the composition of the faecal microbiota of patients suffering from ulcerative colitis differs from that of healthy individuals: they found a reduction in two well-known butyrate-producing bacteria of the Firmicutes phylum, Roseburia hominis and Faecalibacterium prausnitzii. This has been confirmed in other studies. The dysbiosis found in the two inflammatory bowel diseases (IBD) i.e. Crohn’s…

    Philippe Marteau
    Gastroenterologist, Head of the Medico-surgical department of Hepato-gastroenterology, Lariboisière Hospital, Paris. Professor of gastroenterology at Paris 7 University. Philippe Marteau received his PhD from the University Paris XI, France, in 1994. His main research interest is Physiopathology of the human intestinal ecosystem (intestinal microbiota in health and disease): role of the ecosystem in the development of intestinal diseases, especially inflammatory bowel diseases (Crohn’s disease, ulcerative colitis...) and irritable bowel syndrome (IBS); treatment or prevention (1st axis: description of the ecosystem in different physiological situations and pathological conditions -inflammatory bowel disease, cancers, polyps- / 2nd axis: modulation of the ecosystem using probiotics, prebiotics or other food substrates). Philippe Marteau has published >270 publications in peer reviewed scientific journals. He is member of the French Society of Gastroenterology, ECCO and of IOIBD (International Organization of Inflammatory Bowel Diseases), GETAID. He is president of the French “Collégiale des Universitaires d’Hépatogastroentérologie”. He has been principal investigator of several randomized controlled trials using drugs or probiotics in the treatment of various gastrointestinal diseases, especially inflammatory bowel disease and irritable bowel syndrome.
    Share:

    A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.

    • 10 Jan 2014
    • BY Philippe Marteau
    • In Dysbiosis, Gut Microbiota, HCP, Research & Practice, SCFA, Ulcerative Colitis
    • No Comment
    • 0

    Machiels et al. recently described that the composition of the faecal microbiota of patients suffering from ulcerative colitis differs from that of healthy individuals: they found a reduction in two well-known butyrate-producing bacteria of the Firmicutes phylum, Roseburia hominis and Faecalibacterium prausnitzii. This has been confirmed in other studies. The dysbiosis found in the two inflammatory bowel diseases (IBD) i.e. Crohn’s…

    Philippe Marteau
    Gastroenterologist, Head of the Medico-surgical department of Hepato-gastroenterology, Lariboisière Hospital, Paris. Professor of gastroenterology at Paris 7 University. Philippe Marteau received his PhD from the University Paris XI, France, in 1994. His main research interest is Physiopathology of the human intestinal ecosystem (intestinal microbiota in health and disease): role of the ecosystem in the development of intestinal diseases, especially inflammatory bowel diseases (Crohn’s disease, ulcerative colitis...) and irritable bowel syndrome (IBS); treatment or prevention (1st axis: description of the ecosystem in different physiological situations and pathological conditions -inflammatory bowel disease, cancers, polyps- / 2nd axis: modulation of the ecosystem using probiotics, prebiotics or other food substrates). Philippe Marteau has published >270 publications in peer reviewed scientific journals. He is member of the French Society of Gastroenterology, ECCO and of IOIBD (International Organization of Inflammatory Bowel Diseases), GETAID. He is president of the French “Collégiale des Universitaires d’Hépatogastroentérologie”. He has been principal investigator of several randomized controlled trials using drugs or probiotics in the treatment of various gastrointestinal diseases, especially inflammatory bowel disease and irritable bowel syndrome.
    Share: /* */

    A mouse model of colitis shows the relevance of phages on intestinal inflammation

    • 27 Sep 2018
    • BY Andreu Prados
    • In Digestive Health, IBD, Research & Practice, Ulcerative Colitis
    • No Comment
    • 0

    An imbalance in gut microbial communities has been associated with inflammatory bowel diseases (IBD) and research aimed at elucidating the contribution of the microbiota to inflammatory diseases has primarily focused on bacteria. Subsequent and ongoing research has characterized the fungal microbiota (called mycobiome) in patients with IBD. However, even though bacterial and fungal microbiota might be altered in IBD patients,…

    Andreu Prados
    Andreu Prados holds a Bachelor of Science Degree in Pharmacy & Human Nutrition and Dietetics. Science writer specialised in gut microbiota and probiotics, working also as lecturer and consultant in nutrition and healthcare. Follow Andreu on Twitter @andreuprados
    Share:

    A mouse model of colitis shows the relevance of phages on intestinal inflammation

    • 27 Sep 2018
    • BY Andreu Prados
    • In Digestive Health, IBD, Research & Practice, Ulcerative Colitis
    • No Comment
    • 0

    An imbalance in gut microbial communities has been associated with inflammatory bowel diseases (IBD) and research aimed at elucidating the contribution of the microbiota to inflammatory diseases has primarily focused on bacteria. Subsequent and ongoing research has characterized the fungal microbiota (called mycobiome) in patients with IBD. However, even though bacterial and fungal microbiota might be altered in IBD patients,…

    Andreu Prados
    Andreu Prados holds a Bachelor of Science Degree in Pharmacy & Human Nutrition and Dietetics. Science writer specialised in gut microbiota and probiotics, working also as lecturer and consultant in nutrition and healthcare. Follow Andreu on Twitter @andreuprados
    Share: /* */

    Updated evidence on how diet may help in managing inflammatory bowel disease

    • 14 Oct 2019
    • BY Paul Enck
    • In Diet, Gut Microbiota, IBD, Nutrition, Research & Practice
    • No Comment
    • 0

    Although nowadays diet plays only a small part in published guidelines for managing inflammatory bowel diseases (IBDs), there is an increasing amount of evidence that supports the role of diet in patients with IBD, especially at early stages. Evidence of diet modulating intestinal inflammation comes mainly from mice studies. An elegant mice study published in 2018 examined the effects of…

    Paul Enck
    Prof. Dr. Paul Enck, Director of Research, Dept. of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Germany. His main interests are gut functions in health and disease, including functional and inflammatory bowel disorders, the role of the gut microbiota, regulation of eating and food intake and its disorders, of nausea, vomiting and motion sickness, and the psychophysiology and neurobiology of the placebo response, with specific emphasis on age and gender contributions. He has published more than 170 original data paper in scientific, peer-reviewed journals, and more than 250 book chapters and review articles. He is board member/treasurer of the European Society of Neurogastroenterology and Motility and of the German Society of Neurogastroenterology and Motility, and has served as reviewer for many international journals and grant agencies.
    Share:

    Updated evidence on how diet may help in managing inflammatory bowel disease

    • 14 Oct 2019
    • BY Paul Enck
    • In Diet, Gut Microbiota, IBD, Nutrition, Research & Practice
    • No Comment
    • 0

    Although nowadays diet plays only a small part in published guidelines for managing inflammatory bowel diseases (IBDs), there is an increasing amount of evidence that supports the role of diet in patients with IBD, especially at early stages. Evidence of diet modulating intestinal inflammation comes mainly from mice studies. An elegant mice study published in 2018 examined the effects of…

    Paul Enck
    Prof. Dr. Paul Enck, Director of Research, Dept. of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Germany. His main interests are gut functions in health and disease, including functional and inflammatory bowel disorders, the role of the gut microbiota, regulation of eating and food intake and its disorders, of nausea, vomiting and motion sickness, and the psychophysiology and neurobiology of the placebo response, with specific emphasis on age and gender contributions. He has published more than 170 original data paper in scientific, peer-reviewed journals, and more than 250 book chapters and review articles. He is board member/treasurer of the European Society of Neurogastroenterology and Motility and of the German Society of Neurogastroenterology and Motility, and has served as reviewer for many international journals and grant agencies.
    Share: /* */
    • 1 (current)
    • 2
    • 3
    • …
    • 5
    • 6
    • 7
    • Prev
    • Next

    SITEMAP

    Home
    News Watch
    Research & Practice
    About Gut Microbiota
    Events
    Resources
    Media center

    CONTACT US

    contact@gutmicrobiotaforhealth.com

    ABOUT US

    Gut Microbiota for Health has been created by the Gut Microbiota and Health Section of the European Society for Neurogastroenterology & Motility (ESNM), member of United European Gastroenterology (UEG)

    Read more

    EDITED BY:

    The Best Gut Health Blogs of the Year The Best Gut Health Blogs of the Year GMFH selected as one of Healthline’s best gut health blogs of 2016 Our initiative receives a Spanish award
    Privacy Policy  |   Legal Mentions  |   Cookies Policy